Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Seven years on from Sutent and renal cell cancer still needs biomarkers

This article was originally published in Scrip

Executive Summary

Renal cell carcinoma (RCC) treatment is in dire need of relevant biomarkers. With the availability of numerous treatment options in RCC, clinicians are faced with the daunting task of determining the optimal approach with barely any clues as to what will work best. And with 63 drugs in the RCC pipeline, as identified by new analysis from Datamonitor Healthcare, Pipeline: Renal Cell Cancer, the situation is only set to get more complicated.


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts